• Explore /
  • Poster
  • / Updated analysis: Effect of biweekly dosing schedule of trifluridine-tipiracil (TAS-102) on rates of myelosuppression and maintenance of therapeutic efficacy in patients (pts) with previously treated metastatic colorectal cancer (mCRC).

Updated analysis: Effect of biweekly dosing schedule of trifluridine-tipiracil (TAS-102) on rates of myelosuppression and maintenance of therapeutic efficacy in patients (pts) with previously treated metastatic colorectal cancer (mCRC).

Abstract Video & Slides Poster

Authors

Christopher Cann

Christopher G Cann

Vanderbilt University Medical Center, Nashville, TN;

Christopher G Cann , Michael Brian LaPelusa , Sarah Cimino , Brian Grieb , Kristen Keon Ciombor , Rajiv Agarwal , Satya Das , Laura Williams Goff , Dana Backlund Cardin , Shemeka Davis , Jordan Berlin , Cathy Eng

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Colorectal Cancer,Anal Cancer

Sub Track

Symptoms, Toxicities, and Whole-Person Care

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 95)

DOI

10.1200/JCO.2023.41.4_suppl.95

Abstract #

95

Poster Bd #

E12

Abstract Disclosures

Similar Posters

First Author: Christopher G Cann

First Author: Patrick M Boland

First Author: Antoine Adenis

First Author: Yuki Matsubara